These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 20196045

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [The value of incretin based therapies].
    Gallwitz B.
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract] [Full Text] [Related]

  • 6. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE.
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N, Sriwijitkamol A.
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [Abstract] [Full Text] [Related]

  • 11. Pharmacotherapy of hyperglycemia.
    Kulasa KM, Henry RR.
    Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z.
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [Abstract] [Full Text] [Related]

  • 16. [Prospects for incretin-related drugs].
    Kurose T, Seino Y.
    Nihon Rinsho; 2012 May; 70 Suppl 3():703-6. PubMed ID: 22768602
    [No Abstract] [Full Text] [Related]

  • 17. [Antidiabetics and the incretin system].
    Høibraaten E, Folkersen J.
    Tidsskr Nor Laegeforen; 2008 Sep 11; 128(17):1985. PubMed ID: 18787580
    [No Abstract] [Full Text] [Related]

  • 18. Which oral agent to use when metformin is no longer effective?
    Bannon M.
    QJM; 2011 Mar 11; 104(3):183-4. PubMed ID: 21330402
    [No Abstract] [Full Text] [Related]

  • 19. Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist.
    Campbell RK, Neumiller JJ, White J, Sisson E, Kuhn C.
    J Am Pharm Assoc (2003); 2009 Mar 11; 49 Suppl 1():S2. PubMed ID: 19801362
    [No Abstract] [Full Text] [Related]

  • 20. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF.
    Curr Opin Investig Drugs; 2008 Apr 11; 9(4):402-13. PubMed ID: 18393107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.